 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMPHOTERICIN B increase the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMPHOTERICIN B"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: AMPHOTERICIN B: adverse_reactions_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"42[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"58[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Events <sup>a<[0m[31m/[0m[31msup[0m[31m>with an Incidence of &#x2265;[0m[1;31m3[0m[31m% [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m556[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Event<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Percentage [0m[1;31m([0m[31m%[0m[1;31m)[0m
[31mof Patients<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Chills<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m18[0m[31m AMPHOTERICIN B: [0m
[31madverse_reactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Fever<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m14[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Increased Serum Creatinine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Multiple Organ Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Nausea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td AMPHOTERICIN B: adverse_reactions_table: [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypotension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Respiratory Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Vomiting<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Dyspnea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m" AMPHOTERICIN B: adverse_reactions_table: top"[0m[31m><paragraph>Sepsis<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Diarrhea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Headache<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cardiac Arrest<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypertension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: indications_and_usage: INDICATIONS AND USAGE ABELCET ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of [0m
[31mconventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy [0m[1;31m([0m[31mSee DESCRIPTION OF[0m
[31mCLINICAL STUDIES[0m[1;31m)[0m[31m. DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from [0m[1;31m473[0m[31m patients were pooled from three open-label studies in which ABELCET ® was provided for the treatment of patients with[0m
[31minvasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies [0m
[31mdemonstrated effectiveness of ABELCET ® in the treatment of invasive fungal infections as a second line therapy. AMPHOTERICIN B: indications_and_usage: Patients were defined by their individual [0m
[31mphysician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of [0m[1;31m500[0m[31m mg of amphotericin B. Nephrotoxicity was[0m
[31mdefined as a serum creatinine that had increased to >[0m[1;31m2.5[0m[31m mg/dL in adults and >[0m[1;31m1.5[0m[31m mg/dL in pediatric patients, or a creatinine clearance of <[0m[1;31m25[0m[31m mL/min while receiving conventional amphotericin B [0m
[31mtherapy. Of the [0m[1;31m473[0m[31m patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was [0m[1;31m39[0m[31m years [0m[1;31m([0m[31mrange of <[0m[1;31m1[0m[31m to [0m[1;31m93[0m[31m years[0m[1;31m)[0m[31m; [0m[1;31m307[0m[31m patients were [0m
[31mmale and [0m[1;31m166[0m[31m female. Patients were Caucasian [0m[1;31m([0m[1;31m381[0m[31m, [0m[1;31m81[0m[31m%[0m[1;31m)[0m[31m, African-American [0m[1;31m([0m[1;31m41[0m[31m, [0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m, Hispanic [0m[1;31m([0m[1;31m27[0m[31m, [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m, Asian [0m[1;31m([0m[1;31m10[0m[31m, [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, and various other races [0m[1;31m([0m[1;31m14[0m[31m, [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m. AMPHOTERICIN B: indications_and_usage: The [0m
[31mmedian baseline neutrophil count was [0m[1;31m4[0m[31m,[0m[1;31m000[0m[31m PMN/mm3; of these, [0m[1;31m101[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m had a baseline neutrophil count <[0m[1;31m500[0m[31m/mm [0m[1;31m3[0m[31m . Two-hundred eighty-two patients of the [0m[1;31m473[0m[31m patients were considered evaluable for [0m
[31mresponse to therapy; the other [0m[1;31m191[0m[31m patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving [0m[1;31m4[0m[31m doses or less of ABELCET ®[0m
[31m. For evaluable patients, the following fungal infections were treated [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m282[0m[1;31m)[0m[31m: aspergillosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m111[0m[1;31m)[0m[31m, candidiasis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m87[0m[1;31m)[0m[31m, zygomycosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m25[0m[1;31m)[0m[31m, cryptococcosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m16[0m[1;31m)[0m[31m, and fusariosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m11[0m[1;31m)[0m[31m. There were [0m
[31mfewer than [0m[1;31m10[0m[31m evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. AMPHOTERICIN B: [0m
[31mindications_and_usage: However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative [0m
[31mantifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET ® when serum creatinine was above [0m[1;31m2.5[0m[31m mg/dL experienced a decline in serum creatinine during [0m
[31mtreatment [0m[1;31m([0m[31mFigure [0m[1;31m1[0m[1;31m)[0m[31m. Serum creatinine levels were also lower during treatment with ABELCET ® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a [0m
[31mretrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of[0m
[31mpatients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of patients at each time point. [0m
[31mAMPHOTERICIN B: indications_and_usage: Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. In a randomized study of ABELCET ® for [0m
[31mthe treatment of invasive candidiasis in patients with normal baseline renal function, the incidence of nephrotoxicity was significantly less for ABELCET ® at a dose of [0m[1;31m5[0m[31m mg/kg/day than for [0m
[31mconventional amphotericin B at a dose of [0m[1;31m0.7[0m[31m mg/kg/day. Despite generally less nephrotoxicity of ABELCET ® observed at a dose of [0m[1;31m5[0m[31m mg/kg/day compared with conventional amphotericin B therapy at a dose[0m
[31mrange of [0m[1;31m0.6[0m[31m-[0m[1;31m1[0m[31m mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET ® . Renal toxicity of doses greater than [0m[1;31m5[0m[31m mg/kg/day of ABELCET ® has not been formally studied. AMPHOTERICIN [0m
[31mB: indications_and_usage: figure [0m[1;31m1[0m[31m figure [0m[1;31m2[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m9[0m[31m ± [0m[1;31m0.4[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m9.6[0m[31m ± [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m a Data from patients with mucocutaneous leishmaniasis. Infusion rate was [0m[1;31m0.25[0m[31m mg/kg/h. b Data from studies in patients [0m
[31mwith cytologically proven cancer being treated with chemotherapy or neutropenic patients with presumed or proven fungal infection. Infusion rate was [0m[1;31m2.5[0m[31m mg/kg/h. c Data from patients with [0m
[31mmucocutaneous leishmaniasis. Infusion rate was [0m[1;31m4[0m[31m mg/kg/h. d Percentage of dose excreted in [0m[1;31m24[0m[31m hours after last dose. The large volume of distribution and high clearance from blood of amphotericin B [0m
[31mafter the admistration of ABELCET ® probably reflect uptake by tissues. The long terminal elimination half-life probably reflects a slow redistribution from tissues. AMPHOTERICIN B: [0m
[31mclinical_pharmacology: Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased approximately [0m[1;31m34[0m[31m% from day [0m[1;31m1[0m[31m after [0m
[31mthe administration of ABELCET ® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m7[0m[31m days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET ® has not been studied. Tissue concentrations of amphotericin B have been [0m
[31mobtained at autopsy from one heart transplant patient who received three doses of ABELCET ® at [0m[1;31m5.3[0m[31m mg/kg/day: Concentration in Human Tissues Organ Amphotericin B Tissue Concentration [0m[1;31m([0m[31mµg/g[0m[1;31m)[0m[31m Spleen [0m
[1;31m290.0[0m[31m Lung [0m[1;31m222.0[0m[31m Liver [0m[1;31m196.0[0m[31m Lymph Node [0m[1;31m7.6[0m[31m Kidney [0m[1;31m6.9[0m[31m Heart [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m. Brain [0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m6[0m[31m This pattern of distribution is consistent with that observed in preclinical studies[0m
[31min dogs in which greatest concentrations of amphotericin B after ABELCET ® administration were observed in the liver, spleen, and lung; however, the relationship of tissue concentrations of [0m
[31mamphotericin B to its biological activity when administered as ABELCET ® is unknown. Special Populations Hepatic Impairment: The effect of hepatic impairment on the disposition of ABELCET ® is not [0m
[31mknown. Renal Impairment: The effect of renal impairment on the disposition of ABELCET ® is not known. The effect of dialysis on the elimination of ABELCET ® has not been studied; however, amphotericin[0m
[31mB is not removed by hemodialysis when administered as amphotericin B desoxycholate. AMPHOTERICIN B: clinical_pharmacology: Pediatric and Elderly Patients: The pharmacokinetics and pharmacodynamics of [0m
[31mpediatric patients [0m[1;31m([0m[31m≤[0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m and elderly patients [0m[1;31m([0m[31m≥[0m[1;31m65[0m[31m years of age[0m[1;31m)[0m[31m have not been studied.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: nursing_mothers: Nursing Mothers: It is not known whether ABELCET ® is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for [0m
[31mserious adverse reactions in breast-fed infants from ABELCET ® , a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to [0m
[31mthe mother.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET ® does not distinguish [0m
[31mamphotericin B that is complexed with the phospholipids of ABELCET ® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET ® are [0m
[31mnonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET ® , resulting in less than proportional increases in blood concentrations of amphotericin B over a [0m
[31mdose range of [0m[1;31m0.6[0m[31m-[0m[1;31m5[0m[31m mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET ® and amphotericin B desoxycholate are: [0m
[31mPharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET ® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET ® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m5[0m[31m-[0m[1;31m7[0m
[31mdays Mean ± SD Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day for [0m[1;31m42[0m[31m days a Mean ± SD Peak Concentration [0m[1;31m([0m[31m μg/mL[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m ± [0m[1;31m0.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[1;31m)[0m[31m b [0m[1;31m1.1[0m[31m ± [0m[1;31m0.2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Concentration at End of Dosing Interval [0m[1;31m([0m[31mμg/mL[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m ± [0m[1;31m0.3[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[31m b [0m[1;31m0.4[0m
[31m± [0m[1;31m0[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Area Under Blood Concentration-Time Curve [0m[1;31m([0m[31mAUC [0m[1;31m0[0m[31m-24h [0m[1;31m)[0m[31m [0m[1;31m([0m[31mμg*h/mL[0m[1;31m)[0m[31m [0m[1;31m14.0[0m[31m ± [0m[1;31m7.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m[1;31m17.1[0m[31m ± [0m[1;31m5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Clearance [0m[1;31m([0m[31mmL/h*kg[0m[1;31m)[0m[31m [0m[1;31m436.0[0m[31m.± [0m[1;31m188.5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m
[1;31m38.0[0m[31m ± [0m[1;31m15[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Apparent Volume of Distribution [0m[1;31m([0m[31mVd area [0m[1;31m)[0m[31m [0m[1;31m([0m[31mL/kg[0m[1;31m)[0m[31m [0m[1;31m131.0[0m[31m.± [0m[1;31m57.7[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m5.0[0m[31m.± [0m[1;31m2.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Terminal Elimination Half-Life [0m[1;31m([0m[31mh[0m[1;31m)[0m[31m [0m[1;31m173.4[0m[31m ± [0m[1;31m78.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m91.1[0m[31m ± [0m[1;31m40.9[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Amount Excreted in [0m
[31mUrine Over [0m[1;31m24[0m[31m h After Last Dose [0m[1;31m([0m[31m% of dose[0m[1;31m)[0m[31m d [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology_table: <table [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Concentration in Human Tissues<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> [0m
[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Organ<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Amphotericin [0m
[31mB<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tissue Concentration [0m[1;31m([0m[31m&#xB5;g/g[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Spleen<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" AMPHOTERICIN B: clinical_pharmacology_table: Rrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m290.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lung<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m222.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Liver<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m196.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lymph [0m
[31mNode<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Kidney<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6.9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Heart [0m
[1;31m0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m5[0m[31m.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Brain<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: adverse_reactions: ADVERSE REACTIONS The total safety data base is composed of [0m[1;31m921[0m[31m patients treated with ABELCET ® [0m[1;31m([0m[1;31m5[0m[31m patients were enrolled twice and counted as separate [0m
[31mpatients[0m[1;31m)[0m[31m, of whom [0m[1;31m775[0m[31m were treated with [0m[1;31m5[0m[31m mg/kg/day. Of these [0m[1;31m775[0m[31m patients, [0m[1;31m194[0m[31m patients were treated in four comparative studies; [0m[1;31m25[0m[31m were treated in open-label, non-comparative studies; and [0m[1;31m556[0m[31m [0m
[31mpatients were treated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the [0m[1;31m556[0m[31m patients treated with [0m
[31mABELCET ® , [0m[1;31m9[0m[31m% discontinued treatment due to adverse events regardless of presumed relationship to study drug. In general, the adverse events most commonly reported with ABELCET ® were transient [0m
[31mchills and/or fever during infusion of the drug. AMPHOTERICIN B: adverse_reactions: Adverse Events a with an Incidence of ≥[0m[1;31m3[0m[31m% [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m556[0m[1;31m)[0m[31m Adverse Event Percentage [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Patients Chills [0m[1;31m18[0m[31m Fever [0m[1;31m14[0m[31m [0m
[31mIncreased Serum Creatinine [0m[1;31m11[0m[31m Multiple Organ Failure [0m[1;31m11[0m[31m Nausea [0m[1;31m9[0m[31m Hypotension [0m[1;31m8[0m[31m Respiratory Failure [0m[1;31m8[0m[31m Vomiting [0m[1;31m8[0m[31m Dyspnea [0m[1;31m7[0m[31m Sepsis [0m[1;31m7[0m[31m Diarrhea [0m[1;31m6[0m[31m Headache [0m[1;31m6[0m[31m Cardiac Arrest [0m[1;31m6[0m[31m Hypertension [0m[1;31m5[0m[31m Hypokalemia [0m[1;31m5[0m[31m [0m
[31mInfection [0m[1;31m5[0m[31m Kidney Failure [0m[1;31m5[0m[31m Pain [0m[1;31m5[0m[31m Thrombocytopenia [0m[1;31m5[0m[31m Anemia [0m[1;31m4[0m[31m Hyperbilirubinemia [0m[1;31m4[0m[31m Gastrointestinal Hemorrhage [0m[1;31m4[0m[31m Leukopenia [0m[1;31m4[0m[31m Rash [0m[1;31m4[0m[31m Respiratory Disorder [0m[1;31m4[0m[31m Chest Pain [0m[1;31m3[0m[31m Nausea and Vomiting [0m[1;31m3[0m[31m a The [0m
[31mcausal association between these adverse events and ABELCET ® is uncertain. AMPHOTERICIN B: adverse_reactions: The following adverse events have also been reported in patients using ABELCET ® in [0m
[31mopen-label, uncontrolled clinical studies. The causal association between these adverse events and ABELCET ® is uncertain. Body as a whole: malaise, weight loss, deafness, injection site reaction [0m
[31mincluding inflammation Allergic: bronchospasm, wheezing, asthma, anaphylactoid and other allergic reactions Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction, hemoptysis,[0m
[31mtachypnea, thrombophlebitis, pulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation. AMPHOTERICIN B: adverse_reactions: Dermatological: maculopapular rash,[0m
[31mpruritus, exfoliative dermatitis, erythema multiforme Gastrointestinal: acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, [0m
[31mdiarrhea, hepatomegaly, cholangitis, cholecystitis Hematologic: coagulation defects, leukocytosis, blood dyscrasias including eosinophilia Musculoskeletal: myasthenia, including bone, muscle, and [0m
[31mjoint pains Neurologic: convulsions, tinnitus, visual impairment, hearing loss, peripheral neuropathy, transient vertigo, diplopia, encephalopathy, cerebral vascular accident, extrapyramidal syndrome [0m
[31mand other neurologic symptoms Urogenital: oliguria, decreased renal function, anuria, renal tubular acidosis, impotence, dysuria Serum electrolyte AMPHOTERICIN B: adverse_reactions: abnormalities: [0m
[31mhypomagnesemia, hyperkalemia, hypocalcemia, hypercalcemia Liver function test abnormalities: increased AST, ALT, alkaline phosphatase, LDH Renal function test abnormalities: increased BUN Other test [0m
[31mabnormalities: acidosis, hyperamylasemia, hypoglycemia, hyperglycemia, hyperuricemia, hypophosphatemia To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m393[0m[31m-[0m[1;31m4584[0m[31m or by[0m
[31memail at drugsafety@leadiant.com or contact the FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/safety/medwatch.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Amphotericin B does increase the risk of renal failure. The adverse reactions table for Amphotericin B lists [0m[32m"Increased Serum Creatinine"[0m[32m with an incidence of [0m[1;32m11[0m[32m% among patients, which is an [0m
[32mindicator of renal impairment. Additionally, [0m[32m"Kidney Failure"[0m[32m is reported as an adverse event with an incidence of [0m[1;32m5[0m[32m%. However, it is important to note that the causal association between these [0m
[32madverse events and Amphotericin B is uncertain.[0m

[32mSOURCE: AMPHOTERICIN B label[0m
[32mEXTRACT_START_END: Increased Serum Creatinine [0m[32m...[0m[32m Kidney Failure [0m[1;32m5[0m[32m Pain [0m[1;32m5[0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Amphotericin B does increase the risk of renal failure. The [0m
[34madverse reactions table for Amphotericin B lists [0m[34m"Increased Serum Creatinine"[0m[34m with an incidence of [0m[1;34m11[0m[34m% among patients, which is an indicator of renal impairment. Additionally, [0m[34m"Kidney Failure"[0m[34m is [0m
[34mreported as an adverse event with an incidence of [0m[1;34m5[0m[34m%. However, it is important to note that the causal association between these adverse events and Amphotericin B is uncertain.[0m

[34mSOURCE: AMPHOTERICIN B label[0m
[34mEXTRACT_START_END: Increased Serum Creatinine [0m[34m...[0m[34m Kidney Failure [0m[1;34m5[0m[34m Pain [0m[1;34m5[0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether AMPHOTERICIN B increases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Amphotericin B does increase the risk of renal failure, with 'Increased Serum Creatinine' having an incidence of 11% and 'Kidney Failure' reported with an incidence of[0m
[32m5% among patients. However, the causal association between these adverse events and Amphotericin B is uncertain."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"AMPHOTERICIN B increases the risk of renal failure, with 'Increased Serum Creatinine' reported in 11% of patients and 'Kidney Failure' in 5% of patients, although the causal [0m
[32mrelationship is uncertain."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does AMPHOTERICIN B increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether AMPHOTERICIN B increases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Amphotericin B does increase the risk of renal failure, with 'Increased Serum Creatinine' having an incidence of 11% and 'Kidney Failure' reported with an incidence of[0m
[34m5% among patients. However, the causal association between these adverse events and Amphotericin B is uncertain."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"AMPHOTERICIN B increases the risk of renal failure, with 'Increased Serum Creatinine' reported in 11% of patients and 'Kidney Failure' in 5% of patients, although the causal [0m
[34mrelationship is uncertain."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does AMPHOTERICIN B increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether AMPHOTERICIN B increases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that Amphotericin B does increase the risk of renal failure, with [0m[31m'Increased Serum Creatinine'[0m[31m having an incidence of [0m[1;31m11[0m[31m% and [0m[31m'Kidney Failure'[0m[31m reported with an incidence of [0m[1;31m5[0m[31m% [0m
[31mamong patients. However, the causal association between these adverse events and Amphotericin B is uncertain.[0m
[31m        -----[0m
[31m        Final answer: AMPHOTERICIN B increases the risk of renal failure, with [0m[31m'Increased Serum Creatinine'[0m[31m reported in [0m[1;31m11[0m[31m% of patients and [0m[31m'Kidney Failure'[0m[31m in [0m[1;31m5[0m[31m% of patients, although the causal [0m
[31mrelationship is uncertain.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mAMPHOTERICIN B increases the risk of renal failure, with [0m[32m'Increased Serum Creatinine'[0m[32m reported in [0m[1;32m11[0m[32m% of patients and [0m[32m'Kidney Failure'[0m[32m in [0m[1;32m5[0m[32m% of patients, although the causal relationship is uncertain.[0m
